AU715289B2 - Immortalized lines of endothelial brain cells and therapeutic applications thereof - Google Patents

Immortalized lines of endothelial brain cells and therapeutic applications thereof Download PDF

Info

Publication number
AU715289B2
AU715289B2 AU36575/95A AU3657595A AU715289B2 AU 715289 B2 AU715289 B2 AU 715289B2 AU 36575/95 A AU36575/95 A AU 36575/95A AU 3657595 A AU3657595 A AU 3657595A AU 715289 B2 AU715289 B2 AU 715289B2
Authority
AU
Australia
Prior art keywords
cells
endothelial
brain
gene
cell lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU36575/95A
Other languages
English (en)
Other versions
AU3657595A (en
Inventor
Nathalie Chaverot
Pierre-Olivier Couraud
John La Terra
Jerome Quinonero
Francoise Roux
Arthur Donny Strosberg
Jean-Leon Tchelingerian
Lionel Vignais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotech Pharmaceuticals Inc
Original Assignee
Neurotech SA France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotech SA France filed Critical Neurotech SA France
Publication of AU3657595A publication Critical patent/AU3657595A/en
Assigned to NEUROTECH SA reassignment NEUROTECH SA Alteration of Name(s) of Applicant(s) under S113 Assignors: ASSOCIATION POUR LE DEVELOPPEMENT DE L'IMMUNOLOGIE MOLECULAIRE-ADIM
Application granted granted Critical
Publication of AU715289B2 publication Critical patent/AU715289B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU36575/95A 1994-10-10 1995-10-09 Immortalized lines of endothelial brain cells and therapeutic applications thereof Ceased AU715289B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR94/12078 1994-10-10
FR9412078A FR2726005B1 (fr) 1994-10-10 1994-10-10 Lignees immortalisees de cellules endotheliales cerebrales et leurs applications au traitement de differents troubles ou maladies primaires et secondaires neurologiques ou psychiatriques
PCT/FR1995/001313 WO1996011278A1 (fr) 1994-10-10 1995-10-09 Lignees immortalisees de cellules endotheliales cerebrales et leurs applications therapeutiques

Publications (2)

Publication Number Publication Date
AU3657595A AU3657595A (en) 1996-05-02
AU715289B2 true AU715289B2 (en) 2000-01-20

Family

ID=9467723

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36575/95A Ceased AU715289B2 (en) 1994-10-10 1995-10-09 Immortalized lines of endothelial brain cells and therapeutic applications thereof

Country Status (7)

Country Link
EP (1) EP0787197A1 (xx)
JP (1) JPH10507074A (xx)
AU (1) AU715289B2 (xx)
CA (1) CA2202066A1 (xx)
FR (1) FR2726005B1 (xx)
NZ (1) NZ293994A (xx)
WO (1) WO1996011278A1 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035255A2 (en) * 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
US6093553A (en) * 1998-11-25 2000-07-25 Boehringer Ingelheim Pharmaceuticals, Inc. Immortalized brain endothelial cells
WO2000032751A2 (en) * 1998-11-30 2000-06-08 Neurotech (S.A.) Mammalian non-neuronal cells that are modified to store and release a neurotransmitter
FR2787464B1 (fr) * 1998-12-21 2003-01-10 Neurotech Compositions pharmaceutiques comprenant des cellules endotheliales immortalisees pour la detection et/ou le traitement des sources angiogeniques et tout particulierement des cancers
FR2787463B1 (fr) * 1998-12-21 2001-03-30 Neurotech Preparation de cellules de mammifere eventuellement transfectees avec un gene codant pour une substance active et les compositions les contenant
KR100674140B1 (ko) * 1999-03-23 2007-01-26 다카라 바이오 가부시키가이샤 유전자 치료제
WO2001083716A2 (en) * 2000-05-03 2001-11-08 Neurotech S.A. Immortalized lines of endothelial brain cells and therapeutic application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005345A1 (en) * 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
WO1993006222A1 (fr) * 1991-09-24 1993-04-01 Centre National De La Recherche Scientifique (Cnrs) Lignees de cellules endotheliales cerebrales immortalisees avec un oncogene

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE163046T1 (de) * 1990-10-31 1998-02-15 Somatix Therapy Corp Genetische veränderung von endothelzellen
WO1992017569A1 (en) * 1991-04-04 1992-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immortalization of endothelial cells
US5336615A (en) * 1992-01-06 1994-08-09 Yale University Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity
WO1993013807A1 (en) * 1992-01-10 1993-07-22 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy
GB9222931D0 (en) * 1992-11-02 1992-12-16 Sandoz Ltd Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005345A1 (en) * 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
WO1993006222A1 (fr) * 1991-09-24 1993-04-01 Centre National De La Recherche Scientifique (Cnrs) Lignees de cellules endotheliales cerebrales immortalisees avec un oncogene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MED. ABS. 7908023 *

Also Published As

Publication number Publication date
JPH10507074A (ja) 1998-07-14
WO1996011278A1 (fr) 1996-04-18
FR2726005B1 (fr) 1997-01-03
CA2202066A1 (fr) 1996-04-18
FR2726005A1 (fr) 1996-04-26
EP0787197A1 (fr) 1997-08-06
AU3657595A (en) 1996-05-02
NZ293994A (en) 1999-02-25

Similar Documents

Publication Publication Date Title
Takahashi et al. Widespread integration and survival of adult-derived neural progenitor cells in the developing optic retina
US6680198B1 (en) Engraftable human neural stem cells
Villa et al. Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS
Chicoine et al. Mitogens as motogens
Pozas et al. Age-dependent effects of secreted Semaphorins 3A, 3F, and 3E on developing hippocampal axons: in vitro effects and phenotype of Semaphorin 3A (−/−) mice
Tornatore et al. Expression of tyrosine hydroxylase in an immortalized human fetal astrocyte cell line: in vitro characterization and engraftment into the rodent striatum
JPH06503968A (ja) 遺伝子治療のためのレトロウイルスのベクター
Lal et al. Endothelial cell implantation and survival within experimental gliomas.
CA2095300C (en) Use of genetically modified cells to treat defects, disease or damage of the central nervous system
Cunningham et al. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease
Strömberg et al. Target‐specific outgrowth from human mesencephalic tissue grafted to cortex or ventricle of immunosuppressed rats
AU715289B2 (en) Immortalized lines of endothelial brain cells and therapeutic applications thereof
KR19990044606A (ko) 다능성 신경상피세포를 사용한 신경 이식
US7320872B2 (en) Ependymal neural stem cells and method for their isolation
Ojeifo et al. Angiogenesis-directed implantation of genetically modified endothelial cells in mice
Shafit‐Zagardo et al. Novel microtubule‐associated protein‐2 isoform is expressed early in human oligodendrocyte maturation
Quinonero et al. Gene transfer to the central nervous system by transplantation of cerebral endothelial cells
US20040018619A1 (en) Immortalized lines of endothelial brain cells and therapeutic applications thereof
Arnhold et al. Intracerebral transplantation and successful integration of astrocytes following genetic modification with a high-capacity adenoviral vector
WO2001083716A2 (en) Immortalized lines of endothelial brain cells and therapeutic application thereof
US20040115807A1 (en) O-2a progenitors multipotent cells from neurohypophysis
Williams The cellular and molecular changes occurring in the degenerating and regenerating olfactory system
Verity Myelin protein gene expression in developing normal mice, dysmyelinating mutants and an immortalized oligodendrocyte cell line
Ellison Platelet-derived growth factor regulation of oligodendrocyte development: Insights into cell-cell interactions in vivo
KR20130143345A (ko) 신경성장인자를 발현하는 줄기세포 및 이의 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)